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Defining prospective pathways by which zoonoses evolve and
emergeashumanpathogens is critical for anticipatingand controlling
both natural and deliberate pandemics. However, predicting tenable
pathways of animal-to-human movement has been hindered by
challenges in identifying reservoir species, cultivating zoonotic or-
ganisms in culture, and isolating full-length genomes for cloning and
genetic studies. The ability to design and recover pathogens recon-
stituted from synthesized cDNAs has the potential to overcome these
obstacles by allowing studies of replication and pathogenesis with-
out identification of reservoir species or cultivation of primary iso-
lates. Here, we report the design, synthesis, and recovery of the
largest synthetic replicating life form, a 29.7-kb bat severe acute
respiratory syndrome (SARS)-like coronavirus (Bat-SCoV), a likely
progenitor to the SARS-CoV epidemic. To test a possible route of
emergence from the noncultivable Bat-SCoV to human SARS-CoV,we
designed a consensus Bat-SCoV genome and replaced the Bat-SCoV
Spike receptor-binding domain (RBD) with the SARS-CoV RBD (Bat-
SRBD). Bat-SRBD was infectious in cell culture and in mice and was
efficiently neutralized by antibodies specific for both bat and human
CoV Spike proteins. Rational design, synthesis, and recovery of hy-
pothetical recombinant viruses can be used to investigate mecha-
nisms of transspecies movement of zoonoses and has great potential
to aid in rapid public health responses to known or predicted emerg-
ing microbial threats.
emerging pathogens  synthetic biology  vaccine development  zoonoses
Emergence of zoonotic-human pathogens is increasingly recog-nized as a threat to public health (1).Humanpopulation growth
and environmental changes have created new opportunities for
contact between humans and zoonotic organisms that may result in
cross-species transmission and human disease (1, 2). Recent exam-
ples includeRNAviruses such as severe acute respiratory syndrome
coronavirus (SARS-CoV), Ebola, Hanta, Nipah, and Chikungunya
viruses (2). However, the determinants regulating successful trans-
species movement remain poorly understood due to challenges in
identifying viral precursors and animal reservoirs, thereby compli-
cating vaccine and therapeutic design (3). SARS-CoV, which
exemplifies the challenges inherent in studying emerging patho-
gens, was the first 21st century emerging virus to exhibit efficient
human-to-human transmission and rapid global spread (4–6).
Although zoonotic SARS-CoV strains were isolated from civets
and raccoon dogs (7–9), the epidemic likely originated from strains
circulating in bats (Bat-SCoVs) (10–12). Bat CoVs cluster in both
major mammalian CoV taxonomic groups, raising the possibility
that BatCoVsmay be progenitors to all 4 knownpathogenic human
CoVs (11, 13). Bats are also predicted to function as reservoirs for
other important emerging human and animal viruses (14, 15).
Although several complete Bat CoV genome sequences are avail-
able, no Bat CoV has been successfully cultivated in cell culture or
in animals (11, 13), severely limiting the identification of determi-
nants of zoonotic CoV transspecies movement.
The SARS-CoV Spike is a 180-kDa type I membrane glycopro-
tein that contains a well-defined receptor-binding domain (RBD).
The SARS-CoV genome is likely a mosaic of sequences derived
from multiple recombination events, although this hypothesis is
somewhat controversial (16).However, recombinationwithin Spike
has been described often (17), suggesting that the RBDs may be
interchangeable between strains (18–20). During the SARS-CoV
outbreak, evolution in the Spike RBD allowed for more efficient
use of human angiotensin-converting enzyme 2 (hACE2) as a
receptor for entry (21, 22). Because future zoonoses are likely, it is
critical to identify strategies used by viruses to adapt in human
populations. In this study, we have combined phylogenetic and
bioinformatics analyses, large-scale cDNA synthesis, chimeric gene
design, and reverse genetics to generate a consensus Bat-SCoV.
Successful recovery of the infectious chimeric virus, Bat-SRBD,
which includes the RBD within Spike from human SARS-CoV,
demonstrates the plasticity of the CoV type I glycoprotein. The
synthetic reconstruction and recovery of this novel chimeric virus
identifies a necessary genetic element for CoV cross-species trans-
mission, establishes a model system for testing experimental evo-
lution of zoonotic CoVs, and allows for testing of vaccine and
therapeutics against possible future zoonotic strains.
Results
Consensus Bat-SCoV Sequence Design and Construction. When this
study was initiated, 4 Bat-SCoVs had been identified (HKU3–1,
HKU3–2, HKU3–3, and RP3) as the virus reservoir populations
from which SARS-CoV emerged (10–12). Because none had been
recovered in culture, the infectivity of the reported viral genomic
RNA sequences was hypothetical, having been derived from RT-
PCR sequencing of bat fecal or rectal swab samples. Sequence
databases have error frequencies from 1/500 to 1/10,000, making
viable genome reconstruction problematic with increasing size (23).
Therefore, we used the 4 reported Bat-SCoV sequences to establish
a putative consensus Bat-SCoV sequence (GenBank accession no.
FJ211859) and designed cDNA fragments with junctions precisely
aligned to the existing SARS-CoV reverse genetics system [Fig. 1A;
supporting information (SI) Fig. S1] (24). The defined and func-
tional SARS-CoV5UTRand transcriptional regulatory sequences
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were used because the 5UTRs of the Bat-SCoVswere incomplete.
The genomic cDNA fragments were commercially synthesized,
inserted into vectors, assembled into a full-length cDNA, and
transcribed in vitro to yield genomic RNA. Initial attempts to
recover and passage infectious Bat-SCoV failed. Electroporated
cells contained high levels of genome and leader-containing sub-
genomic transcripts on day 2, but not day 5 postelectroporation
(p.e.) (Fig. 1C), indicating that the synthetic consensus Bat-SCoV
genome expressed a functional replicase.We did recover infectious
virus consisting of SARS-CoV genome fragments A–E and Bat
fragment F (Fig. 1 B and D). The resulting virus, Bat-F, encoded a
chimeric Spike. Thus, the amino-terminal two-thirds of SARS-CoV
Spike, including the RBD, and the fusion core contained within the
carboxyl-terminal third of Bat-SCoV Spike can successfully drive
productive infection. Also, because Bat-F contained Bat-SCoV
accessory and structural genes 3 to the Spike gene, these down-
stream ORFs are clearly interchangeable.
Generation and Recovery of Chimeric Bat-SRBD. The ectodomain of
Spike can be exchanged among CoVs, altering host-range specific-
ity (25, 26). To test whether the RBDs of Bat-SCoV and SARS-
CoV were interchangeable, we replaced the Bat-SCoV RBD
(amino acid 323–505) with the SARS-CoV RBD (amino acid
319–518) (27, 28) (GenBank accession no. FJ211860), simulating a
theoretical recombination event that might occur during mixed
infection in vivo (Fig. 1B). After electroporation, Bat-SRBD ge-
nome RNA and leader-containing subgenomic mRNA transcripts
were detected (Fig. 1C), and progeny virions were detected by
plaque assay. After 2 additional passages, the population genome
sequence was identical to the Bat-SRBD molecular clone. How-
ever, 4 nucleotides exhibited dual peaks on the sequencing elec-
tropherograms, suggesting quasispecies variation at these positions
(Table S1). Recovery and passage of Bat-SRBD demonstrated the
functional interchangeability of human and animal SARS-CoV-like
RBDs.
The crystal structure of SARS-CoV RBD complexed with its
receptor, hACE2 (29), implicated 13 residues within the carboxyl
terminus of the RBD (amino acid 426R-518D) in ACE2 engage-
ment. Homology modeling indicated that this receptor-binding
motif (RBM) may be sufficient to allow ACE2 engagement, and
further predicts that inclusion of 6 residues amino-terminal to the
RBM (amino acid 388V-393D)may enhanceACE2 engagement by
functioning as a distal ‘‘hinge.’’ To test this possibility, chimeric
Bat-SCoV genomes were constructed containing either the SARS-
CoV RBM (Bat-SRBM) or the RBM plus the distal hinge residues
(Bat-Hinge) (Fig. 1B). Electroporation yielded genome and sub-
genomic leader-containing transcripts at day 2, but not 5, p.e. (Fig.
1 C andD), and progeny virions could not be successfully passaged
in culture.
Virus Replication in Primate and Murine Cells.We next infected Vero
cells, murine delayed brain tumor (DBT) cells, and DBT cells
expressing hACE2 or civet (c)ACE2 (DBT-hACE2 and DBT-
cACE2) (22) with Bat-SRBD or SARS-CoV at a multiplicity of
infection (MOI) of 0.01 or 1 plaque forming unit (PFU) per cell
(Fig. 2). Bat-SRBDand SARS-CoV exhibited productive growth in
Vero, DBT-hACE2, and DBT-cACE2 cells that was remarkably
similar in kinetics and peak titers (Fig. 2). In contrast, DBT cells
lacking ACE2 expression did not support growth of either SARS-
CoV or Bat-SRBD (data not shown). These data indicate that
Bat-SCoV expressing the SARS-CoV RBD is capable of entering
cells by using ACE2 from humans, nonhuman primates, or civets as
receptor, and replicating efficiently.
Detection of Bat-SRBD Replicase Proteins by SARS-CoV Antibodies.
Comparison of SARS-CoV and Bat-SRBD predicted high, but not
complete, identity of amino acid sequences across replicase proteins
(Table S2). Because antibody cross-reactivity is a potential tool for
detection and analysis of Bat-SCoVs, we tested whether antibodies
specific for SARS-CoV proteins (30) could also detect Bat-SRBD
homologues. Immunoblots were performed by using rabbit poly-
clonal antibodies (pAbs) specific for SARS-CoV nsp1, nsp8, nsp9,
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Fig. 1. Schematic representation of SARS-CoV and Bat-SCoV variants. (A)
Schematic representation of SARS-CoV and Bat-SCoV (GenBank accession no.
FJ211859) genomes and reverse genetics system. (Top) Arrowheads indicate nsp
processing sites within the ORF1ab polyprotein (open arrowheads, papain-like
proteinase mediated; filled arrowheads, nsp5 [3C-like proteinase] mediated).
Immediatelybelowarethefragmentsusedinthereversegenetics system, labeled
A through F. The fragments synthesized to generate Bat-SCoV exactly recapitu-
late the fragment junctions of SARS-CoV with the exception that the Bat-SCoV
has2fragments,Bat-E1andBat-E2,whichcorrespondtotheSARS-Efragment. (B)
Schematic representation showing organization of the SARS-CoV and Bat-SCoV
Spike proteins. The engineered Spike proteins are pictured belowwith the virus
name to the left. Bat-SRBD includes all of the Bat-SCoV Spike sequence except
that the Bat-SCoV RBD (Bat-SCoV amino acid 323–505) is replaced with the
SARS-CoV RBD (amino acid 319–518) (GenBank accession no. FJ211860). Bat-
SRBD-MAincludes theMA15SpikeRBDchangeatSARS-CoVaaY436H.Bat-SRBM
includes theminimal 13 SARS-CoV residues critical for ACE2 contact, resulting in
a chimeric RBD of Bat-SCoV amino acid 323I-429T and SARS-CoV amino acid
426R-518D. Bat-Hinge is Bat-SRBM sequence, with Bat-SCoV amino acid 392L-
397E replaced with SARS-CoV amino acid 388V-393D. Bat-F includes nt 1–24057
of SARS-CoV (to Spike amino acid 855), with the remaining 3 sequence from
Bat-SCoV.Totherightof theschematic representations,observationof transcript
activity andapproximate stock titers at passage 1 (P1) are indicated.ND indicates
no infectious virus detected by plaque assay. (C andD) Presence of genomic and
subgenomic transcripts after electroporation of in vitro transcribed viral RNA.
Band corresponding to mRNA1 indicates the presence of genomic RNA, either
electroporated genomic RNA or progeny genomic RNA, and the presence of a
band corresponding tomRNA9 indicates the presence of leader-containing sub-
genomic RNA, consistent with mRNA transcription.
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and nsp10 (Fig. S2 and SI Materials and Methods). Proteins of the
predicted size were detected in cells infected with SARS-CoV or
Bat-SRBD demonstrating cross-reactivity of the antibodies and
confirming expression of the cognate replicase proteins in Bat-
SRBD.
Neutralization of Bat-SRBD. To examine antigenic relatedness, the
Bat-SCoV Spike was cloned into Venezuelan Equine Encephalitis
viral replicon particle (VRP) vectors, and pools of mouse (m)pAbs
were tested for neutralization of Bat-SRBD infectivity. All Bat-
SCoV Spike-specific sera efficiently neutralized Bat-SRBD, with
50%neutralization titers ranging from 1/100 to 1/400 dilutions (Fig.
3A). In parallel, these sera did not neutralize SARS-CoV infectivity,
suggesting that the antibodies recognize epitopes in Spike outside
the RBD in Bat-SRBD. Because the RBD appears to be the
minimal motif required to alter host range of the Bat-SCoV
precursor, we also tested whether Bat-SRBD could be neutralized
with human monoclonal antibodies (hmAbs S109.8, S227.14, and
S230.15), which recognize unique epitopes within the SARS-CoV
RBDand cross-neutralize human and zoonotic SARS-CoV isolates
in vitro and in vivo (31). The hmAbs neutralized Bat-SRBD,
demonstrating the accessibility of the neutralizing epitopes of
SRBD in the background of the Bat-SCoV Spike (Fig. 3B).
Neutralization also functions as an important safety feature in
design and study of Bat-SRBD viruses.
Bat-SRBD Replicates in Human Airway Epithelial (HAE) Cell Cultures.
Because Bat-SRBD grew equivalently to SARS-CoV in culture, we
tested whether Bat-SRBD could replicate in primary HAEs, which
recapitulate the epithelium of the human conducting airway. We
have previously identified zoonotic SARS-CoV variants that rep-
licated efficiently in Vero cells, but not in HAE cultures (22, 32).
Therefore, HAE cultures provide a more relevant and stringent
measure of the replicative potential of chimeric recombinant zoo-
notic SARS-CoV viruses in the human host. HAE cultures were
inoculated by means of the apical surface and the media sampled
at different times postinfection (p.i.). Peak titers of SARS-CoV and
Bat-SRBD were similar, although Bat-SRBD growth was delayed,
compared with SARS-CoV (Fig. 4A). Because hACE2 is detected
primarily on the apical surface of ciliated cells in HAEs (33), we
looked for differences in targeting of Bat-SRBD and SARS-CoV
infection in HAEs. Histological sections from HAE at 144-h p.i.
were probed with Spike-specific antisera, and localization assessed
by indirect immunofluorescence. For both viruses, Spike was
detected predominantly on the apical surface of ciliated cells (Fig.
4 B and C), but was not detected in nonciliated cells.
SARS-CoV Mouse-Adapted Spike Mutation Enhances Bat-SRBD Repli-
cation inMice. SARS-CoVreplicates inmouse lungs, but causes only
slight morbidity (34, 35). Replication and pathogenesis are en-
hanced in infections of BALB/c mice withMA15, a mouse-adapted
SARS-CoV containing 6 amino acid changes, including a Y436H
substitution in the Spike RBD (36). Although modeling predicts
that Y436H enhances RBD-mACE2 receptor engagement (Fig.
S3), both SARS-CoV and MA15 replicate efficiently in mouse
lungs, complicating assignment of Y436H contributions. To test the
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Fig. 2. Growth of SARS-CoV and Bat-SRBD in 3 different cell types. (A–C) Vero cells (A), DBT-hACE2 cells (B), or DBT-cACE2 cells (C) were infectedwith SARS-CoV
at a MOI  1 (■) or MOI  0.01 (F), or Bat-SRBD at a MOI  1 () or a MOI  0.01 (E). Infected cultures were sampled, in triplicate, at the times indicated and
viral titer was quantified by plaque assay on Vero cells. Error bars indicate SD.
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Fig. 3. Neutralization of the Bat-SRBD by mouse serum and humanmAbs. (A)
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Spikewereused toneutralizeBat-SRBD.Controls includeprebleed serum(■) and
Mouse 1 serum used to neutralize SARS-CoV (). (B) Human mAbs S109.8 (■),
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expressed as the percentage of neutralization. Error bars indicate SD.
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hypothesis that Y436H enhances interaction with mACE2, Bat-
SRBD was constructed with this substitution (Bat-SRBD-MA).
Electroporation with Bat-SRBD-MA genome RNA resulted in
production of infectious virus with titers similar to Bat-SRBD (Fig.
1B). Next, 14-month-old BALB/c mice were infected with Bat-
SRBD, Bat-SRBD-MA, or SARS-CoV. Mice were weighed and
monitored daily for morbidity, and on days 2 and 4 p.i., mice were
euthanized and lungs harvested (Fig. 5). Mice infected with chi-
meric viruses did not exhibit significant weight loss or morbidity
after infection (Fig. 5A). However, although Bat-SRBD replicated
in infected lungs, Bat-SRBD-MA replicated 1.5 logs more effi-
ciently at day 2 (Fig. 5B), providing support for the hypothesis that
the Y436H substitution in Bat-SRBD-MA may improve mACE2
receptor engagement.
Discussion
Reverse genetic systems have revolutionized our understanding of
the molecular basis of viral replication, pathogenesis, and vaccine
design for many virus families. However, application of these
technologies to emerging pathogens has been limited by factors
involved in constructing and manipulating molecular clones and
characterizing recombinant viruses, particularly those with large
genomes. Also, standard approaches for development of infectious
clones have required availability of viral RNA or DNA, and
consequently have been mostly limited to viruses that replicate in
culture. Last, classical approaches to combat emerging or deliber-
ately introduced human pathogens may not allow responses in a
timeframe adequate to significantly reduce mortality or morbidity.
Time Post-infection (h)
3
4
5
6
7
8
2 8 24 48 72 96 120 144
SARS-CoV
Bat-SRBD
V
ira
l T
ite
r 
(L
og
1
0P
F
U
/m
l)
A
B
C
D
Fig. 4. Efficient replicationofBat-SRBDinhumanciliatedairwayepithelial cells.
(A)Growthcurves for SARS-CoVandBat-SRBDwereobtained fromapicalwashes
of human ciliated airway epithelial cell cultures inoculated with either virus.
Sampleswere seriallydilutedand titersdeterminedbyplaqueassayonVero cells.
Titers are expressed as PFU per mL. Both SARS-CoV and Bat-SRBD replicated to
titersof107,althoughBat-SRBDgrowthwasdelayedcomparedwithSARS-CoV.
All inoculations were performed in duplicate. SARS-CoV, F; Bat-SRBD, E. (B–D)
Representative histological sections of HAE 144 h p.i. with SARS-CoV (B), Bat-
SRBD (C), or vehicle alone (D) and probed with mouse polyclonal sera directed
against theBat-CoVSpikeandvisualizedwithmouse-specific secondaryantibod-
ies conjugated to AlexaFluor 488 (green). Detection of Spike immunoreactivity
was localized specifically to the apical surface of ciliated cells indicating that
SARS-CoV and Bat-SRBD both infect ciliated cells after apical inoculation. Note
that at 144 h p.i. cilial morphology shows considerable cytotoxicity. Spike immu-
noreactivity was not observed in nonciliated cell-types. (Scale bar, 5 m.)
Fig. 5. Weight loss and viral replication of Bat-SRBD, Bat-SRBD-MA, and
SARS-CoV in aged BALB/c mice. Ten 14-month-old female BALB/c mice were
infected intranasallywith 105 PFU of the indicated virus or an equivalent volume
(50L)ofPBS. (A)Weightsofall survivingmiceper infectiongroupwererecorded
each day, averaged, and plotted as a percentage of starting weight. Error bars
indicate SD. (B) On days 2 and 4 p.i., 5mice per groupwere killed and lungswere
harvested. Lung homogenates were titered on Vero cells. Circles represent titers
of individual mouse lungs. Bars represent the average titer of each infection
group. BSRBD, Bat-SRBD; BSRM, Bat-SRBD-MA; SARS, SARS-CoV.
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Thus, new methodologies to rapidly recover and test emerging
zoonotic pathogens are critical. Recent studies have provided
crucial steps toward the goal of synthetic reconstruction of large
microbial genomes. The 7.5- and 5.6-kb genomes of poliovirus and
X174, respectively, were reconstructed from known sequences by
using commercially synthesized cDNA fragments and PCR assem-
bly (37, 38). Similarly, the segmented genome of the 1918 strain of
influenza was reconstructed, in part, by using synthetic design (39).
Human endogenous retroviruses were assembled by PCR-directed
assembly of synthetic oligonucleotides into a consensus provirus
(40), and recombinant SARS-CoVs bearing synthetic zoonotic
Spike sequences were derived by our group (22, 32). Last, the
cloning of the 580-kb microbial genome ofMycoplasma genitalium
was reported, although this work has not yet yielded a replicating
organism (41). To our knowledge, no studies to date have used a
synthetic approach to assess potential mechanisms of zoonotic
emergence of a noncultivable virus.
Because it is possible that even minor events of recombination
and mutation-driven evolution can alter CoV population structure
and promote emergence (22, 32, 42), CoVs may select for alter-
ations in discrete regions of Spike to achieve host-range expansion.
The CoV Spike, a type I fusion protein, contains 2 discrete regions,
a carboxyl-terminal S2 region that encodes fusion and heptad
repeat domains in an arrangement shared by other viral attachment
proteins possessing type I architecture (43), whereas the S1 region
encodes the RBD. Studies in our and other laboratories have
identified mutations in both S1 and S2 regions associated with CoV
host-range expansion (42, 44). These 2 regions may also indepen-
dently or cooperatively mediate transspecies expansion and neu-
tralization escape, in that somemAbs that target the SARS-CoVS1
RBDselect for escapemutants in theRBD, but also in the S2 region
(45). These data suggest that coordinated interactions between the
S1 RBD and select S2 domains may be important in epitope
presentation and Spike function.
We have identified several hmAbs that bind distinct, conserved
locations in the SARS-CoV RBD and neutralize strains that
originate from animal and human hosts (31). These hmAbs did
efficiently neutralize Bat-SRBD, an important finding as it was not
previously clear that mAbs targeting the SARS-CoV RBD would
neutralize virus in the context of a different Spike backbone. It is
also informative that antibodies specific for the Bat-SCoV Spike
protein neutralize Bat-SBRD, which expresses a chimeric Spike
protein, but not SARS-CoV, indicating the existence of neutralizing
antibodies that target portions of Spike outside the RBD. Impor-
tantly, these results suggest that hmAbs specific for SARS-CoV, and
by inference the current panel of SARS-CoV vaccines, may provide
significant protection against other SARS-like CoVs that emerge
from zoonotic pools by natural recombination or are deliberately
designed to cross species. Second, both SARS-CoV RBD-specific
hmAbs and Bat-SCoVmpAbs specific for Spike epitopes outside of
the RBD are able to recognize and neutralize virus even in the
setting of a chimeric Spike, providing important safety features for
studies of emerging zoonotic CoVs.
It has been shown that the 5 UTRs of CoVs can influence the
capacity of the virus to replicate in cells (46). Although the 5UTR
in the synthetic Bat-SCoV originated from SARS-CoV, the sole
difference between Bat-SCoV, which was not capable of amplifi-
cation in cell culture, andBat-SRBD,which could be recovered,was
the RBD derived from SARS-CoV. Our results also confirm and
extend a previous report predicting that deletions and mutations
within the Bat-SCoV RBM ablate interaction with hACE2 and
cACE2 molecules (47). Thus, in this report, we show that the CoV
Spike RBD is interchangeable, is sufficient to confer efficient
growth and infectivity in cells from multiple species, and likely
represents a critical determinant of transspecies movement of
zoonotic CoVs.
To protect against future emerging zoonotic pathogens, it is
crucial to develop cell culture and animal models to test vaccines
and therapeutics, ideally against entire families of organisms, such
as CoVs. Both SARS-CoV and Bat-SRBD replicated efficiently in
HAE cultures, providing a direct human airway model for com-
parison of existing and new antivirals. However, Bat-SRBD repli-
cated poorly in vivo, calling for additional modifications to facilitate
studies in mouse models. Robust structural information exists on
the RBD-ACE2 interaction (29), mutations affecting this interac-
tion have been identified (22, 31), and Rosetta-modeling of short
range RBD-mACE2 receptor interfaces can identify key residues
essential for retargeting the host specificity of Bat-SRBD (Fig. S3)
(48). Previous studies had identified a mutation in the RBD of the
MA15 strain, Y436H, but its exact role in vivo was not clear (36).
By using structural modeling algorithms, we predicted that the
Y436H substitution would enhance the interaction of Bat-SRBD
with mACE2. Bat-SRBD-MA did exhibit increased growth effi-
ciency in aged mice. However, this did not result in clinical disease,
suggesting the requirement for additional adaptive changes. For
example, SARS-CoV encodes at least 5 IFN antagonists, predicted
to function in virulence (49–52). Our model system will allow
mapping of the domains in the Bat-SCoV and SARS-CoV genetic
backgrounds involved in regulation of virulence in aged animals.
In this report, sequence and structural information was inte-
grated with synthetic genomics, reverse genetics, and protein design
to recover a zoonotic precursor virus from a hypothetical infectious
sequence. The resulting chimera exhibited cross-reactivity with
previously identified therapeutics and highlighted possible previ-
ously undescribed mechanisms for host-range expansion. Here, we
articulate a model to predict and directly test tenable emergence
pathways. Paired with a greater availability of reagents and thera-
peutics, our studies represent an approach for rapid recovery and
testing of newly identified pathogens, and which may improve
public health preparedness and intervention strategies against
natural or intentional zoonotic-human epidemics.
Materials and Methods
Cells and Viruses. VeroE6 cells (Vero) weremaintained inMEM (Invitrogen), and
delayed brain tumor (DBT, murine astrocytoma) cells were maintained in Dul-
becco’s MEM (Invitrogen) containing 10% FBS. DBT-hACE2 and DBT-cACE2 cells
were cultured as described (22). HAE cells were plated and differentiated as
described (33). SARS-CoVUrbani strain (hereafter, SARS-CoV) and Bat-SCoVwild
typeand chimeric viruseswerepropagatedandassessedbyplaqueassayonVero
cells. All studieswith viable SARS-CoVandSARS-CoV-like viruseswereperformed
in certified BSL3 laboratories in biological safety cabinets, by using safety proto-
cols thatwere reviewed and approved by the Institutional Biosafety Committees
of Vanderbilt University and the University of North Carolina at Chapel Hill.
Determining the Consensus Sequence for Synthetic Bat-SCoV and Conceptual
Design of the Bat-SCoV Clone. HKU3–1 (DQ022305), HKU3–2 (DQ084200),
HKU3–3 (DQ084199), and RP3 (DQ071615) genomes were aligned by using
ClustalXv1.83 to determine a consensus sequence (Fig. S1 and Figs. S4–S6) (Gen-
Bankaccessionno. FJ211859). The consensusBat-SCoV sequencewasdesigned to
ligate interchangeably with the SARS-CoV infectious clone (24). Notably, there
was no consensus at the 5end of the Bat-SCoV genomes, sowe used the 5most
region of SARS-CoV to append the T7 promoter site to the 5 end of the Bat-A
fragment.
Construction of Chimeric Spike Variants. Insertions of SARS-CoV sequence in
place of Bat-SCoV sequence were engineered by using PCR and the primers
shown inTableS3.PCRamplicons forBat-SRBD(GenBankaccessionno. FJ211860)
and Bat-SRBM were generated by using fragments Bat-E2, and SARS-E. PCR
amplicons for Bat-Hinge (Bat-SRBM plus 6 additional residues from SARS-CoV
Spike) were generated by using Bat-SRBM as template. PCR-generated products
were cloned into the Bat-E2 plasmid by using unique 5-BstBI and 3-MscI sites.
Successful insertions of SARS-CoV sequencewere confirmed by restriction diges-
tion and nucleotide sequencing across the region of PCR amplification.
Generation of SARS-CoV and Bat-SCoV Mutant Viruses. Viruses containing
PCR-generated insertions within the viral coding sequence were produced by
using the SARS-CoV assembly strategy (24, 33, 53) with the following modifica-
tions. Briefly, for Bat-F virus, full-length cDNAwas constructedby ligating restric-
tion products from SARS-CoV fragments A–E and Bat-SCoV fragment F, which
required a BglI-NotI digestion. For Bat-SCoV and Bat-SRBD, Bat-SRBM, and Bat-
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Hinge, plasmids containing the7 cDNA fragments of theBat-SCoVgenomewere
digested by using BglI for Bat-A, Bat-B, Bat-C, and Bat-D, BglI andAflII for Bat-E1
and Bat-E2, and BglI and NotI for Bat-F. Digested, gel-purified fragments were
simultaneously ligated together. Transcription was driven by using a T7 mMes-
sagemMachinekit (Ambion),andRNAwaselectroporatedintoVerocells (24,53).
Virus viability was determined by cytopathic effect and progeny viruses were
passagedat lowMOI. RNAwas recovered from infected cellmonolayers by using
TRIzol (Invitrogen) according to the manufacturer’s instructions, and genome
origins were verified by RT-PCR and nucleotide sequencing.
Assay for Bat-SCoV Leader-Containing Transcripts in Electroporated Cells and
Mouse Lungs.Atdays 2 and 5p.e., generationof leader-containingN (ORF9) and
genome (ORF1) transcripts was determined by RT-PCR. Briefly, RT-PCR was per-
formed by using random hexamers (ABI) and SuperScript III (Invitrogen) to
generate first-strand cDNAat an extension temperature of 55 °C for 1 h. Leader-
containing cDNAs were amplified by PCR by using Taq with Thermopol buffer
(NEB)andthefollowingprimers:5-CAGGAAAAGCCAACCAACCTTG(leader)and
5-CGCTACGACCGAACTGAATGCC to detect Bat-SCoV genomic RNA; and leader
and 5-GTGAGAGCTGTGAACCAAGACG to detect mRNA 9 transcripts. Presence
orabsenceofPCRproductswasassessedbyelectrophoresison1.5%agarosegels.
Viral Growth and Plaque Assays.Vero,DBT,DBT-hACE2, orDBT-cACE2 cellswere
infected at a MOI of 1 or 0.01 PFU/cell. After 1 h at 37 °C, the inocula were
removed, cells were washed and samples were taken at different times p.i. To
determineviral titer, sampleswerediluted, inoculatedontoVerocellmonolayers
in 6-well plates for 1 h, and overlaidwith completemedia plus 1%agar. Plaques
were visualized between 48 and 52 h p.i. by neutral red staining (Sigma).
Generation of Polyclonal Bat-SCoV Spike-Specific Sera and Neutralization Assay.
Murine pAbs specific for the Bat-SCoV Spike were generated as previously de-
scribed (33). Neutralizing titers for mpAbs and hmAbs S109.8, S227.14, and
S230.15 were determined by plaque reduction neutralization titer assay
(PRNT50%) (31). The percentage of neutralization was calculated as follows:
1-(number of plaques in the presence of antibody/number of plaques in the
absence of antibody) x 100%.
Infection of Aged BALB/cMice. Teneachof aged (14months) femaleBALB/cmice
(National Institute of Aging) were lightly anesthetized and infected intranasally
with 105 PFU of Bat-SRBD, Bat-SRBD-MA, or SARS-CoV; 5 additional mice were
inoculated with an equivalent volume (50 L) of PBS. Mice were weighed daily
through4days p.i., andondays 2 and4p.i., 5mice of eachgroupwere killed and
lungs harvested for determination of viral titer. Lungs were weighed and ho-
mogenized in 500 L of PBS at 6,000 rpm for 60 s in a MagnaLyser (Roche).
Clarifiedhomogenateswere thendiluted serially, and titerswere determinedby
plaque assay on Vero cells.
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